Your Health, We Care
The most common adverse reactions (≥ 20%) are edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite.
from FDA,2023.03
Capmatinib has shown significant efficacy in the treatment of non-small cell lun···【more】
Release date：2024-11-11Recommended：233
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor act···【more】
Release date：2024-08-08Recommended：222
Capmatinib is a MET inhibitor developed by Novartis specifically for patients wi···【more】
Release date：2024-08-08Recommended：177
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, prim···【more】
Release date：2024-08-08Recommended：195
